Edition:
United Kingdom

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.91USD
19 Oct 2018
Change (% chg)

-- (--)
Prev Close
$8.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
159,633
52-wk High
$14.00
52-wk Low
$4.10

Summary

Name Age Since Current Position

Steven Meyer

60 2017 Independent Chairman of the Board

Saeed Motahari

52 2017 President, Chief Executive Officer, Director

Andrew Long

53 2017 Chief Financial Officer

Franc Fosse

46 2018 Senior Vice President - Corporate Affairs

Venkat Goskonda

Senior Vice President - Research & Development

Steve Sherman

Senior Vice President - Regulatory Affairs

Mark Nance

2018 Chief Legal Officer and General Counsel

Elizabeth Bohlen

2018 Independent Director

Pierre Lapalme

77 2011 Independent Director

Vaseem Mahboob

48 2018 Independent Director

Brian Tambi

72 2010 Independent Director

Trudy Vanhove

52 2018 Independent Director

Rohit Vishnoi

57 2017 Independent Director

Jackie Marcus

2017 IR Contact Officer

Biographies

Name Description

Steven Meyer

Mr. Steven J. Meyer serves as Independent Chairman of the Board of the Company. He has served on our Board since November 2010 and has served as our Chairman of the Board since January 9, 2017. From August 2007 until November 2010, Mr. Meyer served as a director of Insys Pharma. Mr. Meyer has served as a director of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since 2005, Mr. Meyer has served as the chief financial officer of JVM Realty, a private investment firm specializing in the acquisition, re-positioning and management of real estate for investors. Prior to that, Mr. Meyer was employed by Baxter International Incorporated, a global healthcare company that provides renal and hospital products. Mr. Meyer served as the corporate treasurer and international controller and vice president of Global Operations during a 23-year career at Baxter International, Inc. Mr. Meyer earned his MBA in finance and accounting from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Economics from the University of Illinois in Champaign-Urbana. He is an Illinois Certified Public Accountant. We believe that Mr. Meyer’s management experience and his knowledge of the finance and healthcare industries give him a valuable understanding of our industry which qualifies him to serve as Chairman of the Board.

Saeed Motahari

Mr. Saeed Motahari serves as President, Chief Executive Officer, Director of the company, Mr. Motahari has served as our President and Chief Executive Officer and member of the Board since April 2017. Prior to joining the Company, Mr. Motahari served as the chief commercial officer of Purdue Pharma L.P., a pharmaceutical company, from May 2014 to April 2017. From 2004 to 2014, Mr. Motahari worked at Abbott Laboratories and AbbVie, pharmaceutical companies, including serving as vice president of US Specialty Brands – New Launches. Mr. Motahari also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. Mr. Motahari has also led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development. Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada. We believe that Mr. Motahari has sales, operational and business experience in the pharmaceutical industry which qualifies him to serve as our CEO and as a member of our Board.

Andrew Long

Mr. Andrew G. Long serves as Chief Financial Officer of the Company. Andrew G. Long has served as our Chief Financial Officer since August 2017. He most recently served as senior vice president of Global Finance at Patheon, a pharmaceutical company, from 2015 to 2017, where he worked on a number of initiatives leading up to Patheon’s initial public offering. Prior to working at Patheon, Mr. Long spent nine years as vice president of Finance for multiple divisions at Thermo Fisher Scientific. He began his career building financial expertise in various roles at Abbott Laboratories. Mr. Long received his M.B.A. from the Kellogg School of Business at Northwestern University and earned his undergraduate degree in finance from Indiana University. We believe that Mr. Long has the finance and experience in the life science and bio-pharma industries which qualifies him to serve as our CFO.

Franc Fosse

Mr. Franc Del Fosse is Senior Vice President - Corporate Affairs of the Company, Mr. Del Fosse has served as our General Counsel since February 2014. Prior to joining the Company, Mr. Del Fosse was a partner at the law firm of Snell & Wilmer L.L.P. He was an attorney at Snell & Wilmer from 2005-2014. From 2001-2005, Mr. Del Fosse was an associate at the law firm of Shearman & Sterling. Mr. Del Fosse holds a J.D. degree from Columbia University School of Law and an undergraduate degree from Arizona State University. He is a member of the State Bar of California and Arizona.

Venkat Goskonda

Dr. Venkat R. Goskonda is Senior Vice President - Research & Development of the Company. He has been with INSYS since its inception and was pivotal in the development of SUBSYS and SYNDROS, from formulation development to product approval. With over 20 years of research and development experience, Dr. Goskonda leads INSYS’s drug development efforts by spearheading the development of novel and proprietary drug delivery technologies, guiding proof-of-concept trials and generating intellectual property. Dr. Goskonda is a veteran and leader in the development of drug delivery platforms, including sublingual and nasal sprays and oral liquid formulations of poorly soluble compounds. Prior to joining INSYS, Dr. Goskonda was a manager of pharmaceutical development at Unimed Pharmaceuticals, overseeing many facets of product development across oral and transdermal platforms. Dr. Goskonda received his Ph.D. in pharmaceutics from Northeast Louisiana University. He is a co-inventor on more than 50 issued patents and patent applications and is a co-author on several peer-reviewed scientific publications.

Steve Sherman

Mr. Steve Sherman is Senior Vice President - Regulatory Affairs of the Company. He started in sales and marketing, spent time at the FDA in OPDP and has been in Regulatory Affairs for the last 20 years. He has successfully filed several INDs and CTAs, filed orphan drug applications and has helped to file several successful NDAs. While at INSYS, his team has successfully written and obtained approval of the Pediatric Study Plan and NDA for SYNDROS and obtained “rare pediatric disease” status for cannabidiol in Infantile Spasms. Under Mr. Sherman's leadership, Regulatory Affairs has successfully submitted several INDs and developed and implemented the regulatory strategies for obtaining expanded indications for SUBSYS, pursuing multiple indications for cannabidiol, buprenorphine, buprenorphine-naloxone, naloxone and others. He has played a substantive role in advancing drug development of numerous clinical projects ranging from our marketed products, SUBSYS and SYNDROS, to investigational products such as cannabidiol and the sublingual sprays.

Mark Nance

Mr. Mark Nance is Chief Legal Officer and General Counsel of the Company. Nance also worked in the Office of Policy Planning at the U.S. Federal Trade Commission and prior to attending law school served as a commissioned officer in the U.S. Marine Corps. He holds a J.D. from Cornell Law School and a B.A. in Political Science from the University of Missouri.

Elizabeth Bohlen

Ms. Elizabeth Bohlen is Independent Director of the Company. Ms. Bohlen is the chief operating officer of the Archdiocese of Chicago, where she oversees the organization's administrative functions. She joined the Archdiocese in 2011 after 16 years at McKinsey & Co., where, as a partner, she provided strategic counsel to multinational companies across the retail, consumer and healthcare industries. Prior to assuming her current role in 2015, Ms. Bohlen served in a variety of other leadership positions at the Archdiocese of Chicago, including chief financial officer. She began her career as a financial analyst at The First Boston Corp. (now CSFB) and later worked at McKinsey as a management consultant from 1995 to 2011. Her education includes a B.A. in economics from the University of Notre Dame and an M.B.A. from Harvard Business School.

Pierre Lapalme

Mr. Pierre Lapalme serves as Independent Director of Insys Therapeutics, Inc. Mr. Pierre has served on our Board since March 2011. Mr. Lapalme is chairman of the board of Pediapharm Inc., a publicly traded pharmaceutical company traded on the Toronto Stock Exchange, and has served on its board of directors since January 2014. From January 2004 to June 2016, Mr. Lapalme served on the board of directors of BioMarin Pharmaceutical Inc., a publicly traded pharmaceutical company. From August 2004 until January 2015, Mr. Lapalme served as chairman of the board of directors of BioMarin Pharmaceutical Inc. From 2009 to 2016, Mr. Lapalme served on the board of directors of Aeterna Zentaris, Inc., a biopharmaceutical company publicly traded on the Toronto Stock Exchange. From 1995 until his retirement in 2003, he served as the president and chief executive officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry, including chief executive officer and chairman of the board of Rhône-Poulenc Pharmaceuticals, Inc., in Canada, from 1979 to 1994, and senior vice president and general manager of North America Ethicals, a division of Rhône-Poulenc Rorer, Inc. (now known as Sanofi) where he oversaw the development of the ethical pharmaceutical business in the United States, Canada, Mexico and Central America. Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting certain patent protection for pharmaceuticals. Mr. Lapalme also previously served on the board of directors of two other public companies: Sciele Pharmaceuticals Inc. from 2000 to 2008 and Bioxel Pharma from 2004 to 2009. He also served on the board of two private biotech companies.

Vaseem Mahboob

Mr. Vaseem Mahboob is Independent Director of the company. He has served on our Board since January 2018. Mr. Mahboob is the chief financial officer of Endologix, Inc., a medical technologies and device manufacturer. Prior to joining Endologix in October 2015, he served in several financial positions at GE Healthcare, a worldwide leader in medical device development and distribution. His most recent role was chief financial officer of their Global IT business. Prior to this position, he was the chief financial officer of their Eastern and African Emerging Markets, where he oversaw financial operations for medical device distribution sales and service spanning 84 countries and four zones including Russia, Turkey, Middle East and Africa. Prior to this role, Mr. Mahboob was chief financial officer of GE Healthcare's Global Ultrasound Business, which is the most global and profitable within GE Healthcare. Mr. Mahboob also served as chief financial officer of GE Healthcare's Global Magnetic Resonance (MRI) Business, along with several other global financial leadership positions. Mr. Mahboob was at GE from 2000 to 2015 in his various capacities. Mr. Mahboob received a B.A. in Engineering from Bangalore University and a Masters of Business Administration (MBA) in Financial Markets and Institutions & Information Systems from State University of New York, Buffalo, NY. He is also a graduate of GE's highly regarded internal corporate audit staff where he was a senior audit manager. We believe that Mr. Mahboob’s experience in financial operations and oversight, as well as his pharmaceutical industry experience, qualifies him to serve as a member of our Board.

Brian Tambi

Mr. Brian Tambi serves as Independent Director of Insys Therapeutics, Inc. Mr. Tambi has served on our Board since November 2010. From August 2007 until the November 2010, Mr. Tambi served as a director of Insys Pharma. Mr. Tambi has served as a member of the Board of Directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since forming the company in January 2006, Mr. Tambi has served as the chairman of the board, president and chief executive officer of Antrim Pharma (formerly BrianT Laboratories LLC), a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From 1995 to January 2007, Mr. Tambi served as the chairman, president and chief executive officer of Morton Grove Pharmaceuticals, Inc. Prior to Morton Grove, Mr. Tambi served as president of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva), a publicly traded pharmaceutical company. Mr. Tambi also served as chief operating officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University. We believe that Mr. Tambi’s drug development and commercialization expertise in the pharmaceutical industry qualifies him to serve as a member of our Board.

Trudy Vanhove

Dr. Trudy Vanhove is Independent Director of the company. She has served on our Board since April 2018. Since 2012, Dr. Vanhove has served as a vice president of medical affairs and, subsequently, R&D search and evaluation at Jazz Pharmaceuticals, a pharmaceutical company. Dr. Vanhove began her career at Abbott Laboratories in 1996. She has more than 20 years of experience in clinical drug development, medical affairs and business development and is the recipient of numerous awards, patents and scholarships and she has contributed to the medical literature as the lead author or a co-author on dozens of peer-reviewed journal articles. Dr. Vanhove earned an M.D. and a Ph.D. in pharmacology from the Catholic University in Leuven, Belgium. Her education also includes a fellowship in clinical pharmacology at Stanford University and an executive M.B.A. from St. Mary’s College in California. We believe that Dr. Vanhove’s drug development and clinical experience in the pharmaceutical industry qualifies her to serve as a member of our Board.

Rohit Vishnoi

Dr. Rohit Vishnoi is Independent Director of the company. He has served on our Board since May 2017. Dr. Vishnoi has been serving as a member of the board of directors at Outset, a Warburg Pincus portfolio company since 2012. He has been serving as a member of the board of directors of AVOSET since 2017. In addition, he serves on the advisory boards for the Biomedical Engineering departments of Northwestern University and University of Illinois at Chicago. From 2009 to 2015, Dr. Vishnoi served in positions of increasing responsibility at Hospira, a pharmaceutical company. He was the corporate vice president for the Device R&D organization at Hospira where he was responsible for providing strategic and operational direction. He was also a member of the board of directors of the Hospira Foundation. Prior to joining Hospira, Dr. Vishnoi was the vice president for Global Product Development for the Renal Division at Baxter Healthcare. Over a 20-year career at Baxter, he held positions of increasing responsibility in research and development and general management.

Jackie Marcus

Basic Compensation